Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17180867 | 1.00 | SIGMAR1 (0.50) | SIGMAR1CHRM2CHRM1CHRM3ACHE | |
| SCHEMBL956111 | 0.87 | KCNA3 (0.49) | SIGMAR1ACHEALDH1A1HRH1 | |
| SCHEMBL956109 | 0.87 | KCNA3 (0.49) | SIGMAR1ACHEALDH1A1HRH1 | |
| Hydrochloric Acid SCHEMBL954585 | 0.85 | KCNA3 (0.48) | SIGMAR1ACHEALDH1A1HRH1 | |
| Hydrochloric Acid SCHEMBL954583 | 0.85 | KCNA3 (0.48) | SIGMAR1ACHEALDH1A1HRH1 | |
| SCHEMBL17189449 | 0.84 | HRH1 (0.43) | SIGMAR1ACHENPY2RHRH1 | |
| SCHEMBL4186493 | 0.79 | KCNA3 (0.55) | SIGMAR1CHRM2CHRM1CHRM3ACHE | |
| Hydrochloric Acid SCHEMBL10360726 | 0.78 | KCNA3 (0.53) | SIGMAR1CHRM2CHRM1CHRM3ACHE | |
| SCHEMBL11235320 | 0.77 | KCNA3 (0.50) | SIGMAR1ACHE | |
| SCHEMBL9504518 | 0.76 | SIGMAR1 (0.64) | SIGMAR1CHRM2CHRM1CHRM3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121594-B1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-8802856-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802856-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802856-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140051864-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051864-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051864-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8592453-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-8378121-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8378121-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110020231-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110020231-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021787-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021787-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7834185-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834185-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834185-B2 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080207736-A1 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
| US-20080207736-A1 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
| US-20080207736-A1 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207736-A1 | Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM5, CHRM1 | SIGMAR1 434/4885CHRM2 1/4885CHRM1 3/4885 |
| US-20110021787-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | SIGMAR1 434/4885CHRM2 1/4885CHRM1 3/4885 |
| US-20110020231-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | SIGMAR1 434/4885CHRM2 1/4885CHRM1 3/4885 |
| US-20140051864-A1 | QUATERNARY AMMONIUM DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | SIGMAR1 434/4885CHRM2 1/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.